Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide

Alireza Eghtedar, Ildefonso Rodriguez, Hagop Kantarjian, Susan O'Brien, Naval Daver, Guillermo Garcia-Manero, Alessandra Ferrajoli, Tapan Kadia, Sherry Pierce, Jorge Cortes, Farhad Ravandi

Research output: Contribution to journalArticle

Abstract

The incidence and pattern of secondary neoplasms in patients with acute promyelocytic leukemia (APL) treated with all-trans retinoic acid (ATRA)-containing regimens is not well described. We compared 160 patients with APL treated with ATRA plus idarubicin (n = 54) or ATRA plus arsenic trioxide (ATO) (n = 106) for the incidence of secondary cancers per unit time of follow-up. Median follow-up times for the two cohorts were 136 and 29 months, respectively. Nine patients developed secondary cancers in the chemotherapy group. These included two breast cancers, three myelodysplastic syndromes/acute myeloid leukemia, one vulvar cancer, one prostate cancer, one colon cancer and one soft tissue sarcoma. A melanoma and one pancreatic cancer developed in the ATO group. We conclude that treatment of patients with APL using the non-chemotherapy regimen of ATRA plus ATO is not associated with a higher incidence of secondary cancers (p = 0.29) adjusted for unit time of exposure.

Original languageEnglish (US)
Pages (from-to)1342-1345
Number of pages4
JournalLeukemia and Lymphoma
Volume56
Issue number5
DOIs
StatePublished - May 1 2015
Externally publishedYes

Fingerprint

Acute Promyelocytic Leukemia
Tretinoin
Drug Therapy
Incidence
Colonic Neoplasms
Neoplasms
Prostatic Neoplasms
Idarubicin
Vulvar Neoplasms
Myelodysplastic Syndromes
Pancreatic Neoplasms
Acute Myeloid Leukemia
Sarcoma
Melanoma
Breast Neoplasms
arsenic trioxide
Therapeutics

Keywords

  • Arsenic
  • Leukemia
  • Promyelocytic
  • Secondary neoplasm

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide. / Eghtedar, Alireza; Rodriguez, Ildefonso; Kantarjian, Hagop; O'Brien, Susan; Daver, Naval; Garcia-Manero, Guillermo; Ferrajoli, Alessandra; Kadia, Tapan; Pierce, Sherry; Cortes, Jorge; Ravandi, Farhad.

In: Leukemia and Lymphoma, Vol. 56, No. 5, 01.05.2015, p. 1342-1345.

Research output: Contribution to journalArticle

Eghtedar, Alireza ; Rodriguez, Ildefonso ; Kantarjian, Hagop ; O'Brien, Susan ; Daver, Naval ; Garcia-Manero, Guillermo ; Ferrajoli, Alessandra ; Kadia, Tapan ; Pierce, Sherry ; Cortes, Jorge ; Ravandi, Farhad. / Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide. In: Leukemia and Lymphoma. 2015 ; Vol. 56, No. 5. pp. 1342-1345.
@article{3de8181ba38045e283f2d789ed5d1c61,
title = "Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide",
abstract = "The incidence and pattern of secondary neoplasms in patients with acute promyelocytic leukemia (APL) treated with all-trans retinoic acid (ATRA)-containing regimens is not well described. We compared 160 patients with APL treated with ATRA plus idarubicin (n = 54) or ATRA plus arsenic trioxide (ATO) (n = 106) for the incidence of secondary cancers per unit time of follow-up. Median follow-up times for the two cohorts were 136 and 29 months, respectively. Nine patients developed secondary cancers in the chemotherapy group. These included two breast cancers, three myelodysplastic syndromes/acute myeloid leukemia, one vulvar cancer, one prostate cancer, one colon cancer and one soft tissue sarcoma. A melanoma and one pancreatic cancer developed in the ATO group. We conclude that treatment of patients with APL using the non-chemotherapy regimen of ATRA plus ATO is not associated with a higher incidence of secondary cancers (p = 0.29) adjusted for unit time of exposure.",
keywords = "Arsenic, Leukemia, Promyelocytic, Secondary neoplasm",
author = "Alireza Eghtedar and Ildefonso Rodriguez and Hagop Kantarjian and Susan O'Brien and Naval Daver and Guillermo Garcia-Manero and Alessandra Ferrajoli and Tapan Kadia and Sherry Pierce and Jorge Cortes and Farhad Ravandi",
year = "2015",
month = "5",
day = "1",
doi = "10.3109/10428194.2014.953143",
language = "English (US)",
volume = "56",
pages = "1342--1345",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide

AU - Eghtedar, Alireza

AU - Rodriguez, Ildefonso

AU - Kantarjian, Hagop

AU - O'Brien, Susan

AU - Daver, Naval

AU - Garcia-Manero, Guillermo

AU - Ferrajoli, Alessandra

AU - Kadia, Tapan

AU - Pierce, Sherry

AU - Cortes, Jorge

AU - Ravandi, Farhad

PY - 2015/5/1

Y1 - 2015/5/1

N2 - The incidence and pattern of secondary neoplasms in patients with acute promyelocytic leukemia (APL) treated with all-trans retinoic acid (ATRA)-containing regimens is not well described. We compared 160 patients with APL treated with ATRA plus idarubicin (n = 54) or ATRA plus arsenic trioxide (ATO) (n = 106) for the incidence of secondary cancers per unit time of follow-up. Median follow-up times for the two cohorts were 136 and 29 months, respectively. Nine patients developed secondary cancers in the chemotherapy group. These included two breast cancers, three myelodysplastic syndromes/acute myeloid leukemia, one vulvar cancer, one prostate cancer, one colon cancer and one soft tissue sarcoma. A melanoma and one pancreatic cancer developed in the ATO group. We conclude that treatment of patients with APL using the non-chemotherapy regimen of ATRA plus ATO is not associated with a higher incidence of secondary cancers (p = 0.29) adjusted for unit time of exposure.

AB - The incidence and pattern of secondary neoplasms in patients with acute promyelocytic leukemia (APL) treated with all-trans retinoic acid (ATRA)-containing regimens is not well described. We compared 160 patients with APL treated with ATRA plus idarubicin (n = 54) or ATRA plus arsenic trioxide (ATO) (n = 106) for the incidence of secondary cancers per unit time of follow-up. Median follow-up times for the two cohorts were 136 and 29 months, respectively. Nine patients developed secondary cancers in the chemotherapy group. These included two breast cancers, three myelodysplastic syndromes/acute myeloid leukemia, one vulvar cancer, one prostate cancer, one colon cancer and one soft tissue sarcoma. A melanoma and one pancreatic cancer developed in the ATO group. We conclude that treatment of patients with APL using the non-chemotherapy regimen of ATRA plus ATO is not associated with a higher incidence of secondary cancers (p = 0.29) adjusted for unit time of exposure.

KW - Arsenic

KW - Leukemia

KW - Promyelocytic

KW - Secondary neoplasm

UR - http://www.scopus.com/inward/record.url?scp=84932153505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84932153505&partnerID=8YFLogxK

U2 - 10.3109/10428194.2014.953143

DO - 10.3109/10428194.2014.953143

M3 - Article

C2 - 25120050

AN - SCOPUS:84932153505

VL - 56

SP - 1342

EP - 1345

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 5

ER -